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In this work, a method is established to calibrate a model that describes the basic dynamics of DNA damage and repair. The model
can be used to extend planning for radiotherapy and hyperthermia in order to include the biological effects. In contrast to
“syntactic” models (e.g., describing molecular kinetics), the model used here describes radiobiological semantics, resulting in a
more powerful model but also in a far more challenging calibration. Model calibration is attempted from clonogenic assay data
(doses of 0–6Gy) and from time-resolved comet assay data obtained within 6 h after irradiation with 6Gy. It is demonstrated
that either of those two sources of information alone is insufficient for successful model calibration, and that both sources of
information combined in a holistic approach are necessary to find viable model parameters. Approximate Bayesian computation
(ABC) with simulated annealing is used for parameter search, revealing two aspects that are beneficial to resolving the
calibration problem: (1) assessing posterior parameter distributions instead of point-estimates and (2) combining calibration
runs from different assays by joining posterior distributions instead of running a single calibration run with a combined,
computationally very expensive objective function.
1. Introduction
DNA damage and repair is a critical aspect of radiotherapy,
where tumor cells are killed by irradiation. The radiation
induces DNA damage which eventually leads to cell death if
the damage cannot be repaired successfully. Mild hyperther-
mia is a treatment to boost radiotherapy by heating up the
cancer cells to temperatures between 41°C and 43°C. While
the exact working principles of hyperthermia and its interac-
tion with radiotherapy is still subject to research [1], it has
been shown that hyperthermia acts as a radiosensitizer by
affecting the DNA repair that takes place after an irradiation
event [2–5]. In consequence, knowledge about the dynamics
of DNA damage and repair is essential in order to optimize
hyperthermia treatment plans.
For radiotherapy, in silico modeling is employed to assist
in treatment planning decisions. Such planning is based on
Monte Carlo simulations or kernel methods and deliver
dose-volume histograms [6]. Beyond these geometric dose
calculations, approaches to shape the prescribed radiation
dose according to the biological properties of the tumor have
been proposed but are currently not established [7]. The
prescribed dose of radiation is generally divided into frac-
tions that are delivered in subsequent sessions; however, this
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fractionation scheme is usually not optimized on a patient
level, and the dose prescription is chosen based on clinical
trials and experience. While planning software may include
calculators for biological effective dose (BED) and equivalent
dose (EQD2), they are notmodeling biological effects (such as
DNA damage and repair), but rather, they are tools for com-
paring fractionation schemes. Similarly, for hyperthermia,
planning systems for hyperthermia output temperature or
specific absorption rate (SAR) maps exist [8] and calculators
for equivalent doses have been proposed [9, 10]. Yet, a more
profound understanding andmodeling of the aforementioned
radiobiological effects—DNA damage and repair in this con-
text—would yield a better treatment method. For example,
hyperthermia is believed to deactivate DNA repair proteins
for a certain amount of time [2]. If radiation-induced damage
is introduced during this time window, odds of eliminating
the cells increase [11]. Thus, if calibrated correctly, a model
involving DNA damage and repair would be able to quantify
the duration of this window by simulating the de- and reacti-
vation of said proteins.
In this work, a method is established to calibrate a model
that describes the basic dynamics of DNA damage and repair.
This model can then be used to extend planning for radio-
therapy and hyperthermia to include the biological effects
discussed above, i.e., DNA damage and repair: The biological
system is modeled in silico, and a parameter search for model
calibration is performed with the goal to be able to quantify
biological effects for the system of interest. While previous
efforts demonstrated feasibility [12], a thorough analysis of
the calibration process is provided. This analysis reveals that
some parameters remain unidentified. One strength of the
method is that it is able to combine calibration results origi-
nating from different input data sources (i.e., assays). With
this approach, the yet unidentified parameters could be
further refined.
Model calibration requires data which can be obtained
from number sources which are shown in Figure 1: (1)
immunocytochemical assays such as γH2AX, which quantify
DNA repair [13]; (2) comet assay, which quantifies the
amount of DNA damage [14]; this assay is further discussed
in Section 2.3; (3) clonogenic assay, which quantifies clono-
genicity [15] and is discussed in Section 2.2. (4) In a clinical
setting, DNA damage and repair in tumor cells also affects
response evaluation criteria, tumor volume, patient survival,
tumor progression and growth rate, etc. Thus, these data
(yet quite heterogeneous [7] and thus potentially a poor
choice) could, in theory, also be used for model calibration.
These four different options correspond to the four levels
illustrated in Figure 1 on the left. On the right, suitable
models for these types of readout are depicted. Often, these
models merely attempt to replicate some observed readout.
For example, the cell survival curves discussed above usually
exhibit a parabolic nature in the logarithmic domain [16, 17].
Thus, a quadratic model for log ðSÞ is often used for the dose-
response, without further rationale but just as a method for
fitting the existing data. In the past, this approach has been
expanded to a linear-quadratic-linear relationship [18],
again in a mere attempt to mimic experimentally observed
data. Similarly, biostatistical models for comet assay analysis
are able to describe the assay readout but do not model
actual DNA damage and repair, let alone in a dynamic
fashion [19, 20].
Another class of models go one step further and actually
describe underlying molecular principles instead of the mere
assay readout. For example, the H2AX phosphorylation
discussed above can be modeled using a set of differential
equations [21], and the γH2AX readout is derived from the
model. This approach is mechanistic in the sense that it is
directly modeling the kinetics of the γH2AX pathway and
can be seen as syntactic description of molecular mecha-
nisms. Other models including the lethal-potentially-lethal
(LPL) model by Curtis [22] and the model by Vassiliev [23]
and the Γ-LQ model [24] all follow radiobiologically moti-
vated approaches but do not consider hyperthermia. The
AlphaR model [25] takes the effect of hyperthermia into
account, albeit for temperatures above 43.5°C which are not
the focus of this work. Going one step further, the multi-
hit-repair (MHR) model describes radiobiological semantics
[26] instead of mechanics. It was used to derive cell survival
curves [12] as well as comet assay readouts [27]. In addition
to the semantic approach, the MHR model was chosen for
this work because it is bioinspired and in the past, its ability
was shown to explain many radiobiological phenomena.
2. Materials and Methods
In the following sections, the experimental setup (Section
2.1), the different biological assays (Section 2.2 and 2.3), the
model used in this work (Section 2.4), the methods to map
the model state to the readout from experimental assays
Clinical data
Clonogenic assay
Comet assay
In vitro
Survival model
Comet model
Tumor volume, survival, ...
Population models
Emergent cell reaction
Cell survival models
DNA fragment release/repair
Physical damage models
Molecular (signalling) pathways
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Immunocytochemical
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In silico
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Patient tumor-
ecosystem model
Figure 1: Overview of different assays (clonogenic, comet, and
immunocytochemical) capturing different aspects of DNA damage
and repair (cell survival, physical damage, and molecular
pathways). Each assay (left) provides data that correspond with a
suitable model in silico (right). Alternatively, those various aspects
can be captured in a single, holistic model from which synthetic
assay data are derived for comparison. The latter approach is
pursued in this work for emergent cell reactions (clonogenic
assay) and physical DNA fragment repair (comet assay).
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(Section 2.5), and the calibration method (Section 2.6) are
introduced, concluding with a brief section about the soft-
ware and its availability (Section 2.7).
2.1. Experimental Setup. Hyperthermia and irradiation was
performed on cells from the Abrams cell line; they were a
kind gift of Prof. Robert Rebhun (University of California,
Davis, California, USA). These canine osteosarcoma cells
were selected because of their radioresistance (SF2: 0.85)
[28], yet they respond well to hyperthermia as a radiosen-
sitizer (α = 4:6 × 10−3 Gy −1, β = 6:4 × 10−3 Gy −2, and α/β
=0.72Gy with hyperthermia enhancement-factors (EF)
αEF = 6:7 and βEF = 1:2 [29] for hyperthermia performed
as indicated below.)
Cells were kept in DMEM at 37°C in a humidified incuba-
tor with 5% CO2 (MCO-18AC-PE, Sanyo, Osaka, Japan). In
case of a hyperthermia treatment preceding irradiation, the
cells were transferred to another incubator of the same type,
set to 42°C, and exposed to a heat-up phase of approx.
40min, followed by another 60min of treatment time at the
target temperature. The sequence of treatments (hyperther-
mia followed by irradiation) and the treatment time were
chosen to match the clinical practice [30]. To ensure repeat-
ability and quantify thermodynamic effects such as heat
transfer and evaporative cooling, incubators were carefully
calibrated [29]. In case of an experiment without hyperther-
mia treatment, the cells remained in the 37°C incubator.
Upon completion of the hyperthermia treatment time, the
cells were removed from the incubators and irradiated with
a 6 MV linear accelerator (Clinac iX, Varian, Palo Alto,
USA). Adequate dose build-up and optimal homogeneity of
the dose distribution over the irradiation field were ensured
by appropriate layers of Plexiglass. Since the irradiation
device is also used for regular animal patient treatments,
the dose calibration is carried out by a board-certified, qual-
ified medical physicist and is regularly checked with an ioni-
zation chamber calibrated at the Swiss Federal Institute of
Metrology (METAS).
For logistic reasons (transfer time, setup time, and
sequence of irradiation), there was a time-gap of approx.
10min between the end of the hyperthermia treatment and
the beginning of irradiation. Irradiation occurred at doses
between 0Gy and 6Gy with a dose rate of 600MU, corre-
sponding to approx. 6Gy/min. Figure 2 illustrates the timeline
of the experiments. It is important to note that while the time-
line may suggest otherwise, any experimental procedure (clo-
nogenic and comet assay) discussed below is destructive to the
cells. Cells used for a given readout can therefore not be used
again for a later or different readout. Thus, the readout origi-
nates from different batches of cells.
2.2. Clonogenic Assay. Clonogenic assay is a method to quan-
tify the fraction of cells that survive a treatment, in this case
an irradiation event [15]. It works by seeding a number of
cells in a dish such that colonies form around these cells
due to cell division. After 10 days, the number of colonies
are counted and related to the number of cells seeded. If a cell
loses clonogenicity due to the treatment, it will not form a
clone, while cells which survive the treatment (in the sense
of maintaining clonogenicity) will form a colony. The dataset
to model clonogenic cell survival in canine osteosarcoma
Abrams cells used here was previously published, and the
details of the experimental protocol are described in [29].
2.3. Comet Assay. Comet assay is a method to quantify phys-
ical DNA damage in individual cells [14] and was performed
as follows: approximately 1.5 × 105 Abrams cells were seeded
in each well of 6-well plates the day before treatments. Cells
were treated with radiation and/or heat and harvested after
treatments. For this, trypsin was used, and cells were then
resuspended in ice-cold PBS. After centrifugation, cells were
counted in each sample and resuspended in their DMEM
culture medium complemented with 10% DMSO, in an
appropriate volume to reach the concentration of 2 × 105
cells per mL. Samples for cells used in comet assay were then
stored at -80°C. Experiments were repeated 3 times.
Cells from every repeated experiment were thawed on the
same day and run for comet assay (5 different runs were
needed to run all the samples). After thawing and centrifuga-
tion, DMSO was quickly removed and ice-cold PBS added.
Cells were suspended in molten LMAgarose (CometAssay®
LMAgarose, Trevigen) at a ratio of 1/10 (approximately
1500 cells per sample). Cells were embedded in agarose on
a glass slide and left in the dark for 10min at 4°C. Slides were
then immersed in a 4°C lysis solution (CometAssay® Lysis
Solution, Trevigen) for 1.5 h in a room at 4°C. Slides were
then immersed in the electrophoresis running buffer
(8mg/mL NaOH, 2mL/mL 0.5M EDTA pH8, in dH2O)
for 10min at 4°C in the dark. For electrophoresis, slides were
placed in the Trevigen Comet assay tank (CometAssay® Elec-
trophoresis System II, Trevigen) in a cold room, in an exact
volume of 850mL of 4°C electrophoresis solution. Runs
lasted 30min at 21V and 0.3A. Care was taken to maintain
the same temperature and volume of solution between runs
to avoid interrun variability. Slides were finally immersed
twice in dH 2O for 10min each, then in 70% ethanol for
15min at room temperature. For staining, diluted SYBR
Gold (1 : 10 000, SYBR Gold Nucleic Acid Gel Stain, Invitro-
gen) was then added to each spot of dried agarose including
cells, for 15min at room temperature, in the dark. Slides were
rinsed, dried, and stored at room temperature in the dark.
In order to quantify DNA damage, the microscopy
image of the stained comets is analysed with the image
processing software COMET IV, which computes a value
for each cell/comet, indicating the degree of DNA damage.
From the damage metrics offered by the software, the relative
tail intensity (RTI) was chosen because it provides a linear
relationship between the number of DNA strand breaks
and the quantified damage [31, 32]—a property highly
desired for the data-mapping introduced in Section 2.5. The
resulting data was used in a previous publication [27].
2.4. The Multi-Hit-Repair Model. As mentioned in [27], the
MHR model [12] is a dynamic population model where cells
are assigned to populations H i depending on the number of
radiation-induced hits (thus the variable nameH ) they have
accumulated. The variable Hi counts the number of cells in
population H i. A hit is defined in this work as a lesion that
3Computational and Mathematical Methods in Medicine
is hindering the cell from mitosis. In consequence, cells with
one or more hits cannot undergo mitosis until all the hits are
cured by the repair process. Clonogenicity is the ability of
cells to form clones, for which mitosis is a prerequisite. Thus,
only the cells in H 0 are clonogenic. Figure 3 provides a
graphical illustration of the model. Cells can accumulate up
to K hits, corresponding to the length of the aforementioned
chain. The chain length could be infinite, but for an imple-
mentation, K has to be limited. The practical limit for K is
chosen such that no congestion at the end of the chain
occurs. This criterion is met at K = 9; thus, the chain length
was chosen accordingly.
During a simulation run, all cells are clonogenic at first;
thus, they are assigned to population H 0, counted by the
state variableH0. Hits are induced by radiation with dose rate
RðtÞ, which is set to 0Gy/min at any time except during irra-
diation. Thus, RðtÞ is a square pulse that starts at t = 0with an
intensity of 6Gy/min (see Section 2.1); the width of the pulse
corresponds to the administered dose. While RðtÞ > 0, cells
conceptually travel into the chain as they accumulate hits
according to a radiosensitivity parameter α (α in the context
of the MHR model is unrelated to α as used in the linear-
quadratic model mentioned in Introduction). After irradia-
tion, repair processes inside the cells cure the lesions and
thus, cells travel in the opposite direction where they eventu-
ally may reachH 0. This repair is governed by the repair rate
constant cr and modulated by a repair function rð·Þ (see
below). Alternatively, the repair processes may fail, leading
to the death of a cell. This elimination process occurs at a rate
of ceHi. Thus, the differential equations for population H i is
dHi
dt = αR tð ÞHi−1 − αR tð ÞHi − r Hið Þ + r Hi+1ð Þ − ceHi: ð1Þ
DNA repair cannot occur immediately after repair, since
radiation not only induces DNA damage but also damages
the proteins required for repair. The consequent initial
impedance of repair is modeled using the transient biological
dose equivalent (TBDE) Γ:
dΓ
dt = R tð Þ − γΓ: ð2Þ
Γ decays after irradiation and is used in the repair func-
tion to impede repair after irradiation:
r Hið Þ = cr exp −μΓΓð ÞHi: ð3Þ
Since some small amount of damage is already present
before irradiation, initial conditions were chosen to reflect
the damage distribution according to Equation (8) in prior
work [27]. Alternatively, it can be assumed that no damage
is present before irradiation; i.e., H0ð0Þ = 1, Hi>0ð0Þ = 0, and
Γð0Þ = 0. Negligible differences in terms of the model output
were found between these two approaches; thus, the latter,
simpler approach is used in this work. The full set of equa-
tions is given in the supplementary materials; a summary of
the model parameters is presented in Table 1. See [12, 26,
27] for the derivation, validation, and further discussion of
the MHR model.
For hyperthermia, the two variables Y and Λ are intro-
duced to track the state of active (Y) and inactive (Λ)
repair proteins. These variables represent the respective
relative amount of repair protein, and thus, they sum up
to 1; i.e., Y +Λ = 1. The activation and inactivation is
governed by the following differential equations:
dY
dt = −k1Y + k2Λ,
ð4Þ
dΛ
dt = k1Y − k2Λ:
ð5Þ
The rate at which inactive repair protein is reactivated,
k2, is assumed to be constant in prior research [12, 26, 27,
30] and throughout this work. While the reactivation may
be temperature-dependent, the authors are unaware of
any research supporting that hypothesis, thus, following
the principle of assuming simple circumstances whenever
possible and, k2 is not a function of temperature.
The inactivation of repair protein, however, is
temperature-dependent [2, 33, 34]. The rate at which this
occurs, k1, incorporates the Arrhenius law [35] as follows:
k1 = a · 10−3 exp
Ea
R 273:16 + 37ð Þ −
Ea
R 273:16 + Tð Þ
 
: ð6Þ
t
10 days
t
Heat-up Hyperthermia
40 min 60 min ≈ 10 min
40 min 60 min
Clonogenic assayComet assays
No hyperthermia Gap Repair Mitosis
Figure 2: Graphical representation of the experimental treatment. The timeline at the top depicts an experiment without hyperthermia,
where cells are kept at 37∘C, then transferred to the linear accelerator, irradiated (↯), and then left to grow clones. Comet assays are
performed prior to irradiation as well as during the ≈6 h of repair time post irradiation. For clonogenic assay, the clones are fixed and
quantified after 10 days. The timeline at the bottom follows the same scheme, but with the additional hyperthermia treatment including
the ramp-up to and treatment at 42°C. The time axis is not drawn to scale.
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The parameter a is introduced for numeric reasons.
R = 8:314 J·K −1 ·mol −1 is the gas constant, and Ea = 1528
kJ·mol −1 is the activation energy as published in the liter-
ature [12, 36]. It is important to note that Ea may be cell-line
specific; thus, the choice of Ea should be revisited in the
future once such data is available for the Abrams cell line
used here. It is easy to show that the equilibrium of Equations
(4) and (5) are Y ≈ 1 and Λ ≈ 0, respectively, for T = 37 ∘C.
Those values therefore serve as initial conditions as it is
assumed that this equilibrium is reached prior to the hyper-
thermia treatment.
The repair function is extended to modulate the DNA
repair rate with the amount of inactive repair proteins:
r Hið Þ = cr exp −μΓΓ − μΛΛð ÞHi: ð7Þ
This entails that the rate of repair is reduced both in the
presence of inactive repair protein due to thermal effects (Λ
) and after irradiation when the TBDE is high (Γ).
A temperature of T = 42°C is set during the hyperthermia
treatment. Before and after the treatment, the temperature is
set to T = 37°C.
2.5. Model/Readout Mapping. Since the MHR model is
describing radiobiological processes instead of assay read-
outs, methods need to be implemented to map the model to
such readouts. For clonogenic assay, this is relatively straight
forward and was introduced in [12]: H 0 is tracking clono-
genic cells by definition; thus, the surviving number of cells
is readily available in H0. Survival S is therefore found by
evaluating H0 at the end of the simulation, provided the
simulation time is chosen such that the repair process has
completed at the end of the simulation.
The mapping to comet data is somewhat more elaborate
and was introduced in [27]: The comet readout at a given
point in time consists of the quantification of DNA damage
in a number of (typically m = 100) cells. Depending on the
amount of DNA damage, each cell is assigned to a bin hi:
the first bin h0 tracks the cells with little to no damage and
the second bin h1 tracks cells with more damage, etc. The cell
count in each bin and population is normalized such that
〠
K
i=0
~hi = 〠
K
i=0
~Hi = 1: ð8Þ
Finally, the relative bins ~hi can be mapped directly to ~Hi
of the MHR model.
In Section 2.4, a hit was defined as an impact on the cell
that bars it from mitosis until cured. The correct mapping
between physical DNA damage as reported by the comet
assay and the model populations H i presumes knowledge
about how much physical DNA damage constitutes one hit.
In other words, the relative tail intensities quantifying DNA
damage must be scaled prior to the mapping to Hi to main-
tain the semantics implied by the MHR model (i.e., the
H0
r (·) r (·) r (·) r (·)
cececece
𝛼R 𝛼R 𝛼R 𝛼R
H1 H2 H3 HK
Figure 3: High-level illustration of theMHRmodel [27]. The boxes depict the chain structure with the populationsHi; the arrows denote how
cells accumulate hits (to the right), undergo cell death (to the top), or undergo repair (to the left). Below the chain, comet assay pictures
conceptually illustrate how comets with increasingly high relative tail intensities are mapped to populations with increasingly high
numbers of hits.
Table 1: Summary of model parameters including their search
space. The last column indicates the result of parameter search
(see Section 2.6).
Parameter Description Search space
α Radiosensitivity (Gy −1) 0:17 ; 2½ 
cr Repair rate constant (h −1) 0 ; 10½ 
ce Elimination rate constant (h −1) 0 ; 10½ 
μΓ TBDE weighting factor (Gy −1) 0 ; 10½ 
γ TBDE rate constant (h −1) 0 ; 10½ 
a Repair protein deactivation rate (h −1) 0 ; 2½ 
k2 Repair protein activation rate (h −1) 0 ; 0:1½ 
μΛ Hyperthermia weighing factor 0 ; 5½ 
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definition of a hit). In [27], the correct scaling factor was
unknown, and thus, tail intensities between 0 and 4% were
mapped to H 0 arbitrarily (as discussed there, the model
can still be used with a wrong scaling factor, but the param-
eters may lose the meaning they were originally designed
for). In this work, the scaling factor is not fixed to a single,
convenient value arbitrarily. Instead, the procedure is
repeated with different scaling factors within a sensible range.
In order to achieve this, the scaling is formalized by the
variable σ which denotes the largest tail intensity that is still
mapped to H 0. Hence, σ = 0:04 in the above example.
Interestingly, the method failed to reproduce experimen-
tal comet data for small values of σ. For large values of σ, the
resulting α parameter values were in violation of the lower
bound stipulated by Equation (9) (see Figure S1). Only a
small region around σ = 0:03 was free from these issues;
thus, σ = 0:03 was used.
2.6. Approximate Bayesian Computation. Approximate
Bayesian computation (ABC) [37] is used to estimate distri-
butions of model parameters. The method works as follows:
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Figure 4: Top: cell survival curves after parameter search with Equation (11) as objective function: α = 0:19, cr = 0:22, ce = 0:00, μΓ = 0:00,
γ = 3:80, a = 1:00, k2 = 0:01, and μΛ = 3:50 (left); α = 0:23, cr = 5:80, ce = 0:14, μΓ = 1:62, γ = 0:26, a = 0:31, k2 = 1:3 · 10−4, and μΛ = 4:67
(right). The plots at the left result from a parameter search where clonogenic assay data is not considered at all (i.e., comet data only as
published and discussed in [27]). The plots at the right also show results from a parameter search from comet data alone, but the
parameter set producing the best clonogenic cell survival curve (according to Equation (10)) is shown. Since information from clonogenic
assay was used, the left plot exhibits a very poor prediction of experimental data (εclonogenic = 0:12). This shows that the data from comet
assay alone do not capture all information required for a successful parameter search. However, some parameter sets are viable—the plot
at the right does not suffer from this issue (εclonogenic = 4:8 · 10−4)—suggesting the use of a joint approach where data from both assays is
used. Bottom: experimental and synthetic comet readout for the same parameter sets.
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for each parameter, the range of biologically meaningful
parameter values is estimated. For example, with γ = 10 h −1
(the upper boundary of this parameter), repair proteins reac-
tivate very quickly from the irradiation event; the repair
probability recovers to 94% 30min post irradiation. This is
unrealistically high given the typical delays observed experi-
mentally (see Figure 4 and [38]). Since no prior information
is available on a given parameter values’ positions within the
search space ½a ; b, uniform prior distributions with bound-
aries a and b, U½a ; b, are chosen. The boundaries are listed
in Table 1 for each parameter. Determining the lower bound
on α presents a special case: it is easy to show that in the
absence of any repair (i.e., rðH1Þ = 0),
H0 tð Þ = exp −αRtð Þ, ð9Þ
for the duration of irradiation. After irradiation, R = 0,
and thus, H0ðtÞ remains constant. Because H0ðtÞ is mapped
to the fraction of surviving cells (see Section 2.5), a lower
bound for α can be established by solving Equation (9) after
substituting H0ðtÞ for S as reported in the clonogenic assay
and setting t to the point in time at which irradiation ends.
At the beginning of the parameter search, n sets of param-
eters are initialized by drawing from the prior distributions.
Predictions are made by running themodel in a forward fash-
ion, extracting the predicted readout as described in Section
2.5 and comparing it to experimental data. This yields an error
ε according to Equations (10) and (11) (see below).
In each iteration of the search, the parameters are per-
turbed; the new parameter values are kept if ε decreases and
are discarded otherwise. In a simulated annealing fashion
[39], the amount of perturbation is gradually decreased as
the search progresses. A cut-off value of ε = 10−2 was chosen.
In the end, n sets of parameters are left; all of which provide
a satisfactory error. In this work, n = 1000 was chosen with
250 iterations.
The objective function for the parameter search with cell
survival data is
εclonogenic =〠
D
log SDð Þ − log S∧Dð Þð Þ2, ð10Þ
for the radiation doses D, the experimentally obtained
surviving fraction of cells SD, and the predicted surviving
fraction of cells Ŝ.
Similarly, the objective function for the parameter search
with comet data is
εcomet =〠
t>0
〠
K
i=0
~h
tð Þ
i − ~Hi tð Þ
 2
, ð11Þ
for time point t, normalized population ~Hi, and normal-
ized comet readout ~hi as defined in Equation (8). A combined
calibration was attempted with a combined objective func-
tion (see discussion in Section 4).
2.7. Software.Themethods discussed abovewere implemented
in python (version 3.5.2) using the abcpymodule [40] for ABC
(version 0.5.3). R version 3.6.0 was used to create the plots; the
code and data are available online (https://github.engineering
.zhaw.ch/weyl/synthetic_comet). The software can be config-
ured to use either input data from clonogenic assay or input
data from comet assay. Depending on this selection, the corre-
sponding objective function εclonogenic or εcomet is used. The
results shown in Figure 5 are obtained with the software run-
ning on clonogenic mode, i.e., evaluating εclonogenic, while
those in Figure 4 are obtained with the software running in
comet mode, i.e., evaluating εcomet.
3. Results
Two model outputs for cell survival are shown at the top of
Figure 5, as produced by the software running in clonogenic
mode. The examples were chosen according to similar
εclonogenic: for both instances, εclonogenic ≈ 2:5 × 10−3. Experi-
mentally, it would be very challenging (if not impossible) to
discriminate between the two curves. Yet, the parameters
and the dynamics shown at the bottom are very different
from each other: in the left case, most hits have vanished after
2 h, while the same requires 4 h in the right case.
With the software running in comet mode (i.e., minimiz-
ing εcomet), results are shown in Figure 4. The data on the left
represents a random pick from the parameter result set and
produces a cell survival curve very different from cell survival
found experimentally (εclonogenic=0.12). The ones on the right
is the curve with the lowest error found in the set
(εclonogenic = 4:8 · 10−4).
Figure 6 shows a histogram panel of the parameters unre-
lated to hyperthermia (see Figure S2 for parameters a, k2, and
μΛ). In the top row, parameters from the software in
clonogenic mode are shown while in the middle row,
parameters from the software in comet mode are shown.
The bottom row shows the joint distribution, calculated
from the previous two rows. Generally, values for α and ce
are centered around one or two peaks, while, e.g., μΓ is more
uniformly distributed in the comet case, but clonogenic
assay data suggests that the parameter peaks at low values.
In addition to joining the two posterior distributions for
each parameter, a calibration was attempted where the two
objective functions were combined with a weighting factor ξ:
εcombined = εclonogenic + ξεcomet ð12Þ
In order not to prefer any assay source from the other,
errors from the previous single-assay runs were used to select
ξ = 1:68 × 10−3 such that the two terms are of the same order
of magnitude. This attempt failed; the ABC solver never left
its seeding state (see discussion in Section 4).
4. Discussion
The results shown in the previous section clearly call for a
combined approach, where both clonogenic assay and comet
assay data are used as sources of information for parameter
search. However, the traditional approach of combining
two objective functions failed. This is because in the seeding
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state, ABC with simulated annealing rejects samples from the
prior that are above a certain threshold (values up to ε = 10
were tried). Since it is difficult to find parameters that satisfy
both objective functions, the seeding state never completed.
Thus, the computationally much lighter approach with joint
posteriors is proposed, allowing for additional flexibility in
combining further calibration results.
The results in Figure 5 reveal that survival curves lack
sufficient information for MHR model calibration. This is
hardly surprising, as it was argued before that the clonogenic
assay captures information very distant from the process that
is being modeled. On a side-note, any attempt to calibrate a
model with 8 parameters from 5 data points is likely going
to fail, which is yet another reason to include additional data
sources. However, even with this little information, the top
row in Figure 6 reveals regions of interest for some parame-
ters, e.g., for α and ce. On a related note, the resulting
posterior distributions for α and ce are bimodal. This is an
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different parameter values. Bottom: corresponding Hi values in time (no hyperthermia). While the two parameter sets produce similar
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and μΛ = 1:39 (set 1) and α = 0:20, cr = 4:58, ce = 1:31, μΓ = 0:25, γ = 0:20, a = 0:38, k2 = 0:039, and μΛ = 3:20 (set 2).
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important finding that is concealed by a method aiming at
point-estimates, such as differential evolution one used in
[27]. Indeed for the α value, one peak of the histogram corre-
sponds to the range of parameters found in [12], while the
other peak corresponds to the range of parameters found in
[27]. Interestingly, these two regimes also correspond to the
two instances depicted in Figure 5.
Based on the aforementioned rationale, one may assume
that the use of comet assay readouts would cure these issues.
However, Figure 4 demonstrates that this is not the case.
Otherwise, any parameter set would yield an adequate cell
survival curve. Discussing potential explanations for this
observation is critical since the resulting conclusions govern
the choice of further data to address the open issues: for
quantification of the damage, the relative tail intensity is
assessed for approx. 100 cells per assay. This quantification
does not discriminate between cells that have a chance to
reach H 0, cells that have already initiated apoptosis and will
never reach H 0, and cells that are on the brink of death for
other reasons. In fact, the quantification may even contain
cells that are already dead but still have DNA that is visible
in the microscopy image. However, the ability to reach H 0
is essential for producing a survival curve from the model.
Thus, a possible explanation for the inability to achieve suc-
cessful model calibration from comet assay readout alone
could be that the readout does not carry sufficient informa-
tion about the ability to reach H 0. Furthermore, dead cells
that have degraded so far as to not have any quantifiable
DNA whatsoever would not be considered for comet assay,
and the normalization of the 100 cells to a relative histogram
would mostly masquerade their existence: the only way for
dead cells to influence the results is in the ratio ~h0/∑i≠0 ~hi,
since a surviving cell would contribute toH0 (thus increasing
H0), but if the same cell had died, it would not contribute to
any Hi (thus increasing ~Hi for i ≠ 0).
For the parameters cr, γ, and μΓ (Figure 6) as well as the
parameters related to hyperthermia (Figure S2), uniform
posterior distributions are obtained. The method thus reveals
that more input data is required to identify these parameters.
Parameters γ and μΓ relate to a transient repair inability due
to the irradiation event. From Figure 4, it can be seen that this
effect vanishes approx. 30min. after irradiation. Thus, further
data within that time frame could yield better estimates for
those parameters. cr could be identified by running a series of
clonogenic assays at various dose rates. At low dose rates,
irradiation would not be considered as an event but have a
finite duration and repair may start already during
irradiation. Such dose-rate-dependency was shown in the
past to be reproduced by the MHR model [12], and the rate
of repair cr could become identifiable. The hyperthermia
parameters could be refined with data from a study with
varying time-gaps. Such data from clonogenic assay has been
publishedI [9] but not from comet assay and with different
cell lines. As mentioned in Introduction, assessing the repair-
protein reactivation rate constant k2 would be of great clinical
use, as it would allow a better assessment about tolerable
time-gaps (and variation thereof) between irradiation and
hyperthermia. Since the order of the two treatments (i.e.,
hyperthermia prior to versus after irradiation) was shown to
have minimal effect on cell survival [9], additional input
data in this regard would likely not improve the calibration
results. Investigating more cell lines would reveal which
parameters may vary by how much between subjects.
Clonogenic cell survival and comet assay measurements
were shown to be repeatable [14, 29]; thus, it is reasonable
to expect repeatable results from patient biopsies [38]. This
ce
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would allow for a per-patient calibration, e.g., to improve the
treatment plan on a per-patient basis. As mentioned in the
previous paragraph, such an endeavour would require data
from appropriate sources to identify the relevant parameters,
rather than just more amounts of data.
In case the model cannot be calibrated at all despite these
efforts, it could be simplified, for example by replacing the
TBDE Γ with a fixed window of no repair after irradiation,
removing the parameters μΓ and γ. Alternatively, it is con-
ceivable to split the process at the time of the irradiation,
yielding a hyperthermia process that sets up the initial condi-
tions for a subsequent DNA damage and repair process.
Splitting the model in this way could yield closed-form
solutions or approximations thereof for some state variables,
paving the way for a much simpler calibration strategy.
The model and the strategy presented in this work have a
number of potential limitations. First, the model does not
incorporate any mitosis, which occurs without doubt in H 0
until the cells are fixed and the clonogenic assay is performed.
However, one can argue that for a given cell line, any mitosis
would occur at a fixed rate. While the number of cells would
increase, their ratio would remain the same. Because the clo-
nogenic cell survival assays used in this work are normalized,
mitosis cancels out. Some cells may, however die only after a
few cell cycles. This falls in the gap between the last comet
assay and the point in time when clonogenic assay is per-
formed and is not modeled in the MHR model. Second, the
model does not incorporate any effects of direct cytotoxicity,
i.e. thermal cell-killing. This is alleviated by the fact that such
direct cytotoxicity was not observed in any of the control
experiments performed with hyperthermia alone [29]. Third,
the model does not correctly describe inhibition of DNA
repair proteins above a temperature threshold of 42.5°C–
43°C, since those proteins are believed to enter a different
regime above that threshold [35]. While this is a limitation,
it does not affect the work presented here since the highest
temperature applied in vivo and in silico was 42°C.
5. Conclusions
This work demonstrates that a holistic approach is necessary
to calibrate the MHR model parameters. Relying on clono-
genic assay data or comet assay data alone, as it has been
done in the past, proved to be insufficient to establish unam-
biguous model parameters. Even with this combined
approach, some parameters remain unidentified. However,
the ABC method has the advantage of joining existing poste-
rior distributions with distributions obtained from calibra-
tion runs with new input data. This ability is critical since
model calibration with ABC is, despite all its advantages, very
slow. Combining posterior distributions from ABC, however,
is fast. Following this approach, data from different assays
can be combined in a modular fashion without the need of
rerunning the full calibration.
While the application of the method presented is radio-
therapy, hyperthermia, and treatment planning, the method
presented here addresses a more general problem; thus, many
other instances exist where the application of this method
would be of value.
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